secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0000950170-25-106236
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm Q2 net loss $37.3M; explores financing/strategic alternatives; cash $52M
--------------------------------------------------------------------------------

- Total revenue $37.9M; US XPOVIO net product revenue $29.7M (+6% YoY). Net loss $37.3M ($4.32/share).
- FY2025 total revenue guidance reaffirmed $140-155M; US XPOVIO revenue guidance updated to $110-120M.
- Cash, equivalents & investments $52M at June 30; expects liquidity to fund ops into Jan 2026 excluding $24.5M note maturity Oct 2025.
- Phase 3 SENTRY (myelofibrosis) enrollment screening close this week; top-line data expected March 2026.
- Engaged Centerview Partners to explore financing and strategic alternatives to extend cash runway and maximize value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000095017025106236/0000950170-25-106236-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000095017025106236/kpti-20250811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-106236

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer